drugset / Trial / NCT02163421
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the absolute bioavailability and pharmacokinetics of vedolizumab following a single injection of vedolizumab subcutaneously at 3 varying doses.
Timeline
- Start
- 2014-06
- Primary completion
- 2014-12
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vedolizumab | Monoclonal antibody | 54 mg | Subcutaneous |
| Subject | Vedolizumab | Monoclonal antibody | 108 mg | Subcutaneous |
| Subject | Vedolizumab | Monoclonal antibody | 160 mg | Subcutaneous |
| Subject | Vedolizumab | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.